Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
作者： Daria Zdzalik , Barbara Dymek , Paulina Grygielewicz , Pawel Gunerka , Anna Bujak
DOI: 10.1007/S00432-014-1589-3
关键词:
摘要: … -ALK+ ALCL Karpas299 cell line resistant to crizotinib and CH5424802. We found that I1171T and F1174C mutations in ALK … These mutations resulted in diminished inhibition of ALK …
springer.com
paperity.org参考文章(45)
Ren-Yuan Bai, Tao Ouyang, Cornelius Miething, Stephan W. Morris, Christian Peschel, Justus Duyster, Nucleophosmin–anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway Blood. ,vol. 96, pp. 4319- 4327 ,(2000) , 10.1182/BLOOD.V96.13.4319
Swee Sharp, Paul Workman, Inhibitors of the HSP90 molecular chaperone: current status. Advances in Cancer Research. ,vol. 95, pp. 323- 348 ,(2006) , 10.1016/S0065-230X(06)95009-X
Elias Campo, N Lee Harris, Elaine S Jaffe, Stefano A Pileri, Harald Stein, Jurgen Thiele, James W Vardiman, None, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues ,(2017)
Sen Zhang, Frank Wang, Jeffrey Keats, Xiaotian Zhu, Yaoyu Ning, Scott D. Wardwell, Lauren Moran, Qurish K. Mohemmad, Rana Anjum, Yihan Wang, Narayana I. Narasimhan, David Dalgarno, William C. Shakespeare, Juan J. Miret, Tim Clackson, Victor M. Rivera, Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chemical Biology & Drug Design. ,vol. 78, pp. 999- 1005 ,(2011) , 10.1111/J.1747-0285.2011.01239.X
Ruth H. Palmer, Emma Vernersson, Caroline Grabbe, Bengt Hallberg, Anaplastic lymphoma kinase: signalling in development and disease Biochemical Journal. ,vol. 420, pp. 345- 361 ,(2009) , 10.1042/BJ20090387
Anna Kruczynski, Georges Delsol, Camille Laurent, Pierre Brousset, Laurence Lamant, Anaplastic lymphoma kinase as a therapeutic target. Expert Opinion on Therapeutic Targets. ,vol. 16, pp. 1127- 1138 ,(2012) , 10.1517/14728222.2012.719498
Elena Ardini, Maria Menichincheri, Luisa Rusconi, Paola Magnaghi, Paolo Orsini, Nilla Avanzi, Andrea Lombardi Borgia, Marcella Nesi, Tiziano Bandiera, Gianpaolo Fogliatto, Jay A. Bertrand, Roberto T. Bossi, M. Beatrice Saccardo, Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors. Biochemistry. ,vol. 49, pp. 6813- 6825 ,(2010) , 10.1021/BI1005514
Yael P Mossé, Megan S Lim, Stephan D Voss, Keith Wilner, Katherine Ruffner, Julie Laliberte, Delphine Rolland, Frank M Balis, John M Maris, Brenda J Weigel, Ashish M Ingle, Charlotte Ahern, Peter C Adamson, Susan M Blaney, Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study Lancet Oncology. ,vol. 14, pp. 472- 480 ,(2013) , 10.1016/S1470-2045(13)70095-0
Young Lim Choi, Manabu Soda, Yoshihiro Yamashita, Toshihide Ueno, Junpei Takashima, Takahiro Nakajima, Yasushi Yatabe, Kengo Takeuchi, Toru Hamada, Hidenori Haruta, Yuichi Ishikawa, Hideki Kimura, Tetsuya Mitsudomi, Yoshiro Tanio, Hiroyuki Mano, EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors The New England Journal of Medicine. ,vol. 363, pp. 1734- 1739 ,(2010) , 10.1056/NEJMOA1007478
A. P. Kornev, N. M. Haste, S. S. Taylor, L. F. Ten Eyck, Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism Proceedings of the National Academy of Sciences of the United States of America. ,vol. 103, pp. 17783- 17788 ,(2006) , 10.1073/PNAS.0607656103